SC

Strategy Canon

Sermo: sourced choices

44 product and go-to-market choices, oldest first. Back to the case study

  1. 2006-09Product · Initial product Sermo launched in September 2006 as a free, advertising-free online community restricted to U.S. physicians for discussing cases and treatments. SR37
  2. 2007-01-25Go_To_Market · Venture funding (Series B) Sermo raised a $9.5M Series B led by SoftBank Capital with Longworth Venture Partners. SR2
  3. 2007-06Product · Partner content Under the AMA partnership Sermo members received free full-text access to AMA journal articles. SR3
  4. 2007-06Go_To_Market · Physician price Sermo charged physicians nothing and sold no advertising, earning revenue from clients who paid to see anonymized physician trend data. SR3
  5. 2007-06Go_To_Market · Association partnership Sermo and the AMA agreed an in-kind exchange: AMA gained client-level access to Sermo; Sermo members gained AMA journal access. SR3
  6. 2007-09Product · Verification fix After Medgadget published how non-physicians could register using public license data, Sermo re-authenticated members with data that should be available only to the physician. SR6
  7. 2007-09Product · Contribution incentives Members voted on posts, and Sermo paid physicians bonuses for posts and votes judged valuable after a topic closed. SR5
  8. 2007-09Go_To_Market · Investor pricing Financial firms paid roughly $100,000 to $500,000 a year to observe discussions and pose questions to members. SR5
  9. 2007-09-07Go_To_Market · Venture funding (Series C) Sermo raised a $25M Series C led by Legg Mason, with Longworth and SoftBank Capital returning. SR4
  10. 2007-09-12Product · Core use About half of Sermo's activity in September 2007 was physicians seeking and giving informal consultations, with about 26,000 users on the site. SR46
  11. 2007-10Product · Membership verification At registration Sermo matched a physician's identity and credentials against databases of licensed physicians. SR9
  12. 2007-10Product · Sponsor content format Pfizer's content entered the community through contextual 'hotspots' rather than banner ads or branding. SR9
  13. 2007-10Go_To_Market · First paying segment Palestrant targeted financial services and government as Sermo's first customers, with pharma added later. SR9
  14. 2007-10-14Go_To_Market · First pharma sponsor Pfizer became Sermo's first pharmaceutical partner, able to contribute clinical content and join discussions. SR7
  15. 2008-10Product · Investor product Sermo built a Healthcare Exchange on Bloomberg terminals (BDRUG screen) offering physician newsfeeds and alerts, breaking-news and custom surveys, panels and direct physician contact (MDconnect). SR10
  16. 2008-10-28Go_To_Market · Distribution via Bloomberg Sermo distributed its physician-insight products to Bloomberg's roughly 250,000 terminal users through tiered subscriptions. SR10
  17. 2009Go_To_Market · Partnership lapse The AMA declined to renew the two-year partnership after reviewing Sermo's new terms. SR12
  18. 2009-03-09Go_To_Market · Published revenue model Sermo published its 'information arbitrage' model on a 'How We Make Money' page, sold access to physician discussion mostly to pharma, and let Bloomberg subscribers see member comments on companies and products. SR47
  19. 2009-04Product · Client access to the community Paying clients could not take part in physicians' discussions but could view survey results and post their own surveys to members. SR45
  20. 2009-07-10Go_To_Market · Member advocacy campaign Sermo publicized a 4,156-member survey saying the AMA did not speak for physicians. SR11
  21. 2009-12-07Go_To_Market · Customer segment shift Sermo moved its sales focus from financial-services firms to pharmaceutical and medical-device makers and made cash-flow and profitability priorities. SR13
  22. 2010-07-14Product · Community redesign A 2010 redesign added advanced search, personalized real-time activity, multi-image posts and sections for events, conferences and jobs. SR14
  23. 2012-03Product · Identity on site Members registered under real names but could post under handles and leave profiles blank. SR16
  24. 2012-03Go_To_Market · Research services and honoraria Sermo sold focus groups, surveys and sentiment analysis to pharma, device and CRO clients and paid participating physicians honoraria. SR16
  25. 2012-03-28Go_To_Market · Sponsorship and premium content Under new CEO Tim Davenport, Sermo sold sponsorship and premium content to pharma and device companies and partnered with Joslin Diabetes Center. SR17
  26. 2012-05Product · Mobile consultation Sermo released iConsult, an iPhone app for physicians to seek colleagues' input on cases. SR20
  27. 2012-07-19Go_To_Market · Sale to a research firm Sermo's investors sold the company to WorldOne, a healthcare market-research data-collection firm, for an undisclosed price. SR18
  28. 2013Go_To_Market · Pharma awareness campaigns Sermo offered clients 'awareness campaigns' on the site aimed at influencing physician sentiment about specific drugs and medical devices. SR44
  29. 2013-04-03Go_To_Market · Expansion financing WorldOne secured a $35M commitment from Deerfield Management partly to take Sermo into new markets. SR21
  30. 2013-09-30Product · Panel integration WorldOne moved its U.S. physician research network onto the Sermo platform. SR22
  31. 2014-03-12Go_To_Market · Survey honoraria Sermo paid members about $10 to $40 per market-research survey. SR23
  32. 2014-05Product · Research product suite The combined company offered MedLIVE rapid surveys, the DocTANGO health game and the SermoSolves case-discussion app, grouped into Intelligence and Engagement pillars. SR24
  33. 2015-04-08Product · Cross-border community Sermo opened to UK physicians with a shared channel for UK and U.S. doctors, keeping anonymous physician-only discussion as its core feature. SR26
  34. 2016-04-18Product · Posting identity and activity About 90% of Sermo members posted under usernames, and its 550,000 global members produced 33,000 posts, 626,000 comments and 6,000 case consultations in the prior year. SR48
  35. 2016-04-18Go_To_Market · Research volume and honoraria Sermo ran about 700,000 market-research surveys a year, paid members more than US$16M a year in honoraria and counted 15 of the top 20 U.S. pharma companies as clients. SR48
  36. 2016-05-10Product · Rapid research tool Sermo launched RealTime, a tool for clients to run fast, repeated surveys of healthcare professionals. SR27
  37. 2016-05-10Go_To_Market · Geographic expansion Sermo opened its social network to physicians in 30 countries, starting from the UK in 2015. SR28
  38. 2017Product · Drug ratings Sermo introduced physician-submitted Drug Ratings, open only to verified physicians, later made public in 2025. SR1
  39. 2019-02Product · Member experience rebuild With Abry's investment Sermo rebuilt the membership experience to change how doctors communicate on the platform. SR30
  40. 2019-02-06Go_To_Market · Private-equity recapitalization Abry Partners recapitalized Sermo, buying out earlier investors. SR29
  41. 2023-02-08Go_To_Market · Bolt-on acquisitions Sermo acquired Payer Access and Charter Oak to reach payer decision-makers and oncologists for research clients. SR31
  42. 2025-08-01Go_To_Market · Client pricing Sermo sells physician insights and engagement to pharma and agencies on a pay-per-completed-engagement basis. SR34
  43. 2025-10-30Product · Self-serve advertising Sermo launched Engagement Manager, a self-serve tool for health brands to run campaigns aimed at its verified HCP members. SR35
  44. 2026-09-23Product · Posting identity and utilities Sermo lets members post anonymously or under their name and offers patient calling (Sermo Mobile), drug ratings and case discussion. SR36